COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chiranjib ChakrabortyAshish Ranjan SharmaManojit BhattacharyaGarima SharmaSang-Soo LeeGovindasamy AgoramoorthyPublished in: Journal of medical virology (2020)
COVID-19 leads to mortality of several patients and the cytokine storm is reportedly critical in the patients. To reduce the cytokine storm, we would like to propose the interleukin (IL) 6 receptor (IL-6R) antagonist therapy for the COVID-19 patients. Two humanized monoclonal antibodies are in clinical trial following IL-6R antagonist therapies namely tocilizumab and sarilumab. However, researchers and physicians should look for more IL-6R antagonists for the therapy of cytokine storm syndrome severe acute respiratory syndrome coronavirus 2 infected persons to enhance the therapeutic options for cytokine storm.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- coronavirus disease
- end stage renal disease
- clinical trial
- ejection fraction
- newly diagnosed
- primary care
- rheumatoid arthritis
- peritoneal dialysis
- type diabetes
- stem cells
- risk factors
- open label
- coronary artery disease
- case report
- patient reported outcomes
- monoclonal antibody